Gene Expression Markers For Breast Cancer Prognosis

Patent No. EP2230319 (titled "Gene Expression Markers For Breast Cancer Prognosis") was filed by Genomic Health on Jan 14, 2004. The application was issued on Oct 21, 2015.

Patent Summary

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
COOLEY UKJul 21, 2016COOLEY UK

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2230319

GENOMIC HEALTH
Application Number
EP10162868A
Filing Date
Jan 14, 2004
Status
Opposition Rejected
Feb 9, 2018
Publication Date
Oct 21, 2015